> Australia's Pharmaxis has begun a Phase III trial of Bronchitol, its experimental therapy for bronchiectasis. Results are expected by the mid-part of next year. Report
> Chembio Diagnostics has received an approvable letter for its rapid HIV test and expects formal approval in the "very near future." Report
> TeGenero is offering £5,000 to six men who suffered organ failure at the beginning of a Phase I trial, provided they agree not to sue. Lawyers for several of the men said that TeGenero wants the men to agree to binding arbitration to arrive at a fair compensation figure. Article
> TriPath Imaging has received approval for a new breast cancer test. Report
> SCOLR Pharma plans to raise $11.8 million in a stock offering. Report
> The UK's Lectus Therapeutics has acquired the assets of NeuroServe, an electrophysiology company which tests compounds on ion channels for pharmaceutical and biotech clients. Release
> Isis Pharmaceuticals has licensed its HIV therapy--Isis 5320--to Imquest. Report
> Predix Pharmaceuticals of Lexington, MA, which recently announced a definitive agreement to merge with EPIX Pharmaceuticals, announced that it has completed a Phase Ib clinical trial to study the pharmacodynamics and tolerability of PRX-08066 in 15 adults. Release
> Inspire Pharmaceuticals has received a $1.25 million milestone from Santen Pharmaceutical. Release
> China's Aida Pharmaceuticals has agreed to purchase the remaining outstanding shares of Shanghai Qiaer Bio-Technology Co. for $495,650. Release
And Finally… New studies discount the possibility that mercury in fillings can harm children. Article